Business Description
Biomark Diagnostics Inc
NAICS : 621510
SIC : 8071
ISIN : CA09073K1084
Description
Biomark Diagnostics Inc. is a Canadian life sciences company focused on the development and commercialization of blood-based, liquid biopsy tests for the early detection and monitoring of cancer. Its technology platform combines metabolomics and other "omics" data with machine learning and proprietary biomarker panels to identify cancer-related signals in a simple blood sample. The company's lead programs target lung cancer and other solid tumors, with tests intended to support screening, diagnosis, treatment monitoring, and recurrence detection. Its primary customers and collaborators are expected to include hospitals, clinical laboratories, oncology practices, and research institutions, with an initial focus on the North American market. Biomark Diagnostics generates no meaningful product revenue at present and relies on research collaborations, licensing arrangements, and equity financing to fund development and regulatory validation of its diagnostic platform.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.62 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 2.23 | |||||
Debt-to-EBITDA | -1.31 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 6.3 | |||||
Beneish M-Score | -3.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.6 | |||||
3-Year EBITDA Growth Rate | 14.5 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 3.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.55 | |||||
9-Day RSI | 52.1 | |||||
14-Day RSI | 44.24 | |||||
3-1 Month Momentum % | 5.56 | |||||
6-1 Month Momentum % | -5 | |||||
12-1 Month Momentum % | 58.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.29 | |||||
Quick Ratio | 1.29 | |||||
Cash Ratio | 1.18 | |||||
Days Sales Outstanding | 1673.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.1 | |||||
Shareholder Yield % | -0.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5117.86 | |||||
Net Margin % | -5085.71 | |||||
EBITDA Margin % | -3453.57 | |||||
FCF Margin % | -3833.69 | |||||
OCF Margin % | -3825.65 | |||||
ROE % | -197.56 | |||||
ROA % | -66.55 | |||||
ROIC % | -153.16 | |||||
3-Year ROIIC % | -192.31 | |||||
ROC (Joel Greenblatt) % | -221.78 | |||||
ROCE % | -122.99 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 500 | |||||
PB Ratio | 100 | |||||
Price-to-Tangible-Book | 50 | |||||
EV-to-EBIT | -39.86 | |||||
EV-to-EBITDA | -55.56 | |||||
EV-to-Revenue | 1918.75 | |||||
EV-to-FCF | -49.35 | |||||
Earnings Yield (Greenblatt) % | -2.51 | |||||
FCF Yield % | -2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biomark Diagnostics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 0.028 | ||
| EPS (TTM) (C$) | -0.014 | ||
| Beta | 0.4583 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 1.04 | ||
| Volatility % | 34.62 | ||
| 14-Day RSI | 44.24 | ||
| 14-Day ATR (C$) | 0.011036 | ||
| 20-Day SMA (C$) | 0.494 | ||
| 12-1 Month Momentum % | 58.33 | ||
| 52-Week Range (C$) | 0.27 - 0.64 | ||
| Shares Outstanding (Mil) | 106.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biomark Diagnostics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biomark Diagnostics Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biomark Diagnostics Inc Frequently Asked Questions
What is Biomark Diagnostics Inc(XCNQ:BUX)'s stock price today?
The current price of XCNQ:BUX is C$0.50. The 52 week high of XCNQ:BUX is C$0.64 and 52 week low is C$0.27.
When is next earnings date of Biomark Diagnostics Inc(XCNQ:BUX)?
The next earnings date of Biomark Diagnostics Inc(XCNQ:BUX) is .
Does Biomark Diagnostics Inc(XCNQ:BUX) pay dividends? If so, how much?
Biomark Diagnostics Inc(XCNQ:BUX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers